Basic and clinical studies of the combined multi-targeting therapy of leukemia
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 6
- DOI:
- 10.3760/cma.j.issn.1009-9921.2008.06.001
- Key Word:
- 白血病;靶向疗法;维甲酸;砷剂;冬凌草素;Leukemia;Target therapy;Tretinoin;Arsenicals;Rubescensine
Abstract： The success of ATRA and ATO in APL treatment furuishes the first model of molecular target-based induction of differentiation and apoptosis.Two drugs all target PML-RARα oncoprotein through different moieties and induce APL cells differentiation and apoptosis.In acute myeloid leukemia M2b,we reveal that gain-of-function of C-kit coexists with persistent AML1-ETO,suggesting that abnormal C-kit may serve as a therapeutic target in AML L-M2b Oridonin becomes a potential candidate target drug which specifically degrades AML1-ETO protein. Experiment in vitro proves the combinatorial effectiveness of imatinib and cytarabin in the treatment of chronic myelogenous leukemia(CML).Imatinib is an inhibitor of abnormal protein tyrosine kinases activity. While arsenic agent triggers the degradation of bcr-abl, and combination of the two drugs in treating CML leads to a better outcome.
- [1]姚尔固.白血病的靶向治疗[J].2005,(1).
- [2]曹志成.白血病的综合治疗新进展[J].2007,(4).
- [3]孟利花,马梁明.STI571治疗C-Kit阳性肿瘤的研究进展[J].2005,(2).
- [4]I, Cunningham,T S, Gee,L M, Reich,etc.Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital.[J].1989,73.
- [5]李俊娥,邬维礼,王振义,等.As2S2诱导K562细胞凋亡及其机制[J].2002,(11).
- [6]Gartland L,Hiebert SW,Klug CA,etc.Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.[J].2002,22(15).
- [7]Miao Y,Chen Z,Rowley JD,etc.A previously unidentified alternatively spliced isoform of t(8; 21) transcript promotes leukemogenesis.[J].2006,12(8).
- [8]A, Melnick,J D, Licht.Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.[J].1999,93.
- [9]Zhu, J,Li, G,Gao, L,etc.Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia[J].2008,105(6).
- [10]Z X, Shen,G Q, Chen,J H, Ni,etc.Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.[J].1997,89.
- [11]Peterson LF,Zhang DE.The 8; 21 translocation in leukemogenesis.[J].2004,23(24).
- [12]J D, Rowley,H M, Golomb,C, Dougherty.15/17 Translocation, a Consistent Chromosomal Change in Acute Promyelocytic Leukaemia.[J].1977,1.
- [13]Licht JD.AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8; 21) AML.[J].2001,20(40).
- [14]de The, H.,Chomienne, C..The t(15; 17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor...[J].1990,347(6293).
- [15]Shi JY,Wang YY,Liu YW,etc.AML1-ETO and C-KIT mutation/overexpression in t(8; 21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.[J].2005,102(4).
- [16]Gilliland DG,Kelly LM.Genetics of myeloid leukemias.[J].2002,3(0).
- [17]Look, A. Thomas.Oncogenic transcription factors in the human acute leukemias. (cover story)[J].1997,278(5340).